Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

This study evaluated the effect of empagliflozin on postprandial glucose (PPG) and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM). Methods: Patients (N?=?60; baseline mean [SD] HbA1c 7.91 [0.80]%;body mass index 24.3 [3.2] kg/m2) were randomized to receive empagliflozin 10?mg (n?=?20), empagliflozin 25?mg (n?=?19) or placebo (n?=?21) once daily as monotherapy for 28?days. A meal tolerance test and continuous glucose monitoring (CGM) for 24?hours were performed at baseline and on days 1 and 28. The primary endpoint was change from baseline in area under the glucose concentration-time curve 3?hours after breakfast (AUC1?4h for PPG) at day 28. Results: Adjusted mean (95%) differences versus placebo in changes from baseline in AUC1-4h for PPG at day 1 were ?97.1 (?126.5, ?67.8) mg???h/dl with empagliflozin 10?mg and ?91.6 (?120.4, ?62.8) mg???h/dl with empagliflozin 25?mg (both p?
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Source Type: research